Document Detail


Drug interaction between tacrolimus and ertapenem in renal transplantation recipients.
MedLine Citation:
PMID:  23195020     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
To show drug interactions between tacrolimus and ertapenem, we retrospectively evaluated 13 renal transplant recipients who had been treated with ertapenem for urinary tract infections during prescription of a constant dose. The mean dose of tacrolimus to achieve desired therapeutic concentrations decreased significantly after beginning ertapenem. The decrease from 0.079 mg/kg to 0.043 mg/kg occurred 2 days after initiation of ertapenem (P < .005). These results suggest that ertapenem, which is not metabolized through the cytochrome (CYP) P450 3A metabolic pathway, interacts with tacrolimus by an unknown mechanism. This report recommends tacrolimus concentration monitoring and dose reductions when the two drugs are administered in combination.
Authors:
F Bora; I Aliosmanoglu; H Kocak; A Dinckan; H B Uslu; F Gunseren; G Suleymanlar
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transplantation proceedings     Volume:  44     ISSN:  1873-2623     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3029-32     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Department of General Surgery, Dicle University Medical Facility, Diyarbakir, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic Association of Interleukin-1? (-511C/T) and Its Receptor Antagonist (86-bpVNTR) Gene Polymor...
Next Document:  Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompati...